uniQure (NASDAQ:QURE) Trading Up 11.3% – Should You Buy?

uniQure N.V. (NASDAQ:QURE)’s stock price was up 11.3% during trading on Thursday . The company traded as high as $30.19 and last traded at $28.9920. Approximately 1,525,505 shares traded hands during trading, a decline of 30% from the average daily volume of 2,177,645 shares. The stock had previously closed at $26.06.

Analyst Ratings Changes

A number of equities analysts have recently commented on QURE shares. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. UBS Group set a $95.00 price objective on shares of uniQure in a report on Thursday, September 25th. William Blair downgraded uniQure from an “outperform” rating to a “market perform” rating in a report on Tuesday. The Goldman Sachs Group dropped their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, HC Wainwright cut their price objective on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $66.75.

uniQure Stock Up 6.2%

The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The firm has a 50-day moving average price of $41.62 and a two-hundred day moving average price of $24.04. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -7.19 and a beta of 0.59.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares in the company, valued at approximately $11,975,150. This represents a 6.45% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 244,316 shares of company stock worth $10,328,181. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Trust Co. NA acquired a new position in shares of uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp increased its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. Main Management ETF Advisors LLC lifted its holdings in shares of uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after buying an additional 912 shares in the last quarter. Profund Advisors LLC grew its stake in shares of uniQure by 24.6% in the third quarter. Profund Advisors LLC now owns 17,084 shares of the biotechnology company’s stock valued at $997,000 after acquiring an additional 3,368 shares in the last quarter. Finally, Ballentine Partners LLC bought a new position in uniQure during the third quarter worth about $301,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.